Tamsulosin Hydrochloride + DutasterideThird Party Manufacturing in India

Tamsulosin Hydrochloride plus Dutasteride is a synergistic fixed-dose combination that targets benign prostatic hyperplasia through two distinct and complementary pharmacological mechanisms. Tamsulosin is a selective antagonist of alpha-1 adrenergic receptors, with approximately 7 to 38 times greater selectivity for the alpha-1A subtype compared to the alpha-1B subtype. The alpha-1A receptor is the predominant subtype in the prostatic stroma, prostatic capsule, bladder neck, and proximal urethra. By competitively blocking the binding of endogenous catecholamines norepinephrine and epinephrine to these receptors, tamsulosin relaxes the smooth muscle fibres in the prostate gland and bladder neck, reducing the dynamic component of bladder outlet obstruction and improving urinary flow rate within hours of administration. Dutasteride is a competitive, time-dependent inhibitor of both type 1 and type 2 isoforms of the enzyme 5-alpha reductase, which catalyses the conversion of testosterone to dihydrotestosterone, the primary androgen responsible for prostate growth. By inhibiting both isoenzymes, dutasteride reduces serum dihydrotestosterone levels by over 90 percent and intraprostatic DHT levels by approximately 80 percent, leading to involution of the prostate epithelium, reduction in prostate volume, and progressive improvement in urinary symptoms over weeks to months. The combination of tamsulosin's rapid symptomatic relief with dutasteride's disease-modifying volume reduction provides comprehensive BPH management superior to either agent alone.

Therapeutic Uses

Tamsulosin Hydrochloride + Dutasteride is prescribed for the treatment of:

• Benign Prostatic Hyperplasia: This fixed-dose combination is indicated for the treatment of moderate to severe benign prostatic hyperplasia in men with prostate enlargement, providing both rapid symptom relief and progressive disease modification.
• Acute Urinary Retention Prevention: The combination reduces the risk of acute urinary retention and the need for BPH-related surgery compared to either monotherapy alone, as demonstrated in long-term clinical trials.
• Lower Urinary Tract Symptoms: Patients with International Prostate Symptom Scores of 20 or higher and prostate volumes of 30 mL or greater experience superior symptom reduction with combination therapy compared to tamsulosin or dutasteride alone.
• Long-Term BPH Management: The combination is suitable for patients requiring ongoing treatment for BPH, with sustained improvement in urinary flow rate, reduced post-void residual volume, and improved quality of life over extended treatment periods.

Why Manufacturers Choose Tamsulosin Hydrochloride + Dutasteride

The tamsulosin plus dutasteride fixed-dose combination is the gold standard medical therapy for moderate to severe BPH, widely prescribed by urologists and primary care physicians for patients with symptomatic prostate enlargement. Available as 0.4 mg + 0.5 mg tablets, this combination addresses both the dynamic and static components of bladder outlet obstruction through complementary mechanisms. Indian manufacturers benefit from the large and growing geriatric male population driving consistent BPH prescription demand. The fixed-dose combination format offers improved patient adherence compared to separate administration of two tablets, creating a premium product positioned above monotherapy generics. The established domestic and export markets, well-characterised stability profiles of both APIs, and straightforward bilayer or homogeneous tablet formulation technology make this combination an attractive addition to any urology product portfolio. This makes Tamsulosin + Dutasteride one of the most sought-after combination products for third party manufacturing in India, with consistent demand from PCD franchise networks.